Skip to main content

$0.040 0.004 (11.11%)

High

$0.04

Low

$0.04

Trades

37

Turnover

$81,892

Volume

2,106,389
30 June 2023 at 3:45pm
Register to track NTI and receive email alerts.
Subject
NTI Ann: Appointment of Allan Cripps as Non-Executive Director

NTI Ann: Appendix 2A

NTI Ann: Appendix 2A

NTI Ann: Update - Proposed issue of Securities - NTI

NTI Ann: Update - Proposed issue of Securities - NTI

NTI Ann: Results of Meeting

NTI Ann: Neurotech initiates Phase I/II Open Label Study into Autism

NTI Ann: Quarterly Report and Appendix 4C

NTI Ann: Update - Proposed issue of Securities - NTI

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Disclosure Document

NTI Ann: Appendix 2A

NTI Ann: Change of Director's Interest Notice

NTI Ann: Initial Director's Interest Notice

NTI Ann: Notice of General Meeting/Proxy Form

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Appointment of Krista Bates as Non-Executive Director

NTI Ann: Appendix 2A

NTI Ann: Human Clinical Trial Update

NTI Ann: Appendix 2A

NTI Ann: Appendix 2A

NTI Ann: Appendix 2A

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Disclosure Document

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Strategic Cultivation Partnership with CannaPacific

NTI Ann: Notice of Expiry of Listed Options

NTI Ann: Appendix 2A

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Proposed issue of Securities - NTI

NTI Ann: Neurotech Expands License with Dolce Cann Global

NTI Ann: Neurotech Secures $3.56m in Funding

NTI Ann: Appendix 4D and Half Year Accounts

NTI Ann: Trading Halt

NTI Ann: Phase One and Two Clinical Program Update

NTI Ann: Quarterly Report and Appendix 4C

NTI Ann: Q&A with NTI Company Chairman, Brian Leedman

NTI Ann: Change of Director's Interest Notice

NTI Ann: Appendix 2A

NTI Ann: Results of Meeting

NTI Ann: Successful Completion of In Vitro Studies

NTI Ann: Change of Director's Interest Notice x 3

NTI Ann: Update - Proposed issue of Securities - NTI

NTI Ann: Update - Proposed issue of Securities - NTI

NTI Ann: Disclosure Document

NTI Ann: Appendix 2A

Register to track NTI and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
IPD
MX1
RSH
SOM